Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne and pattern alopecia, often characterised by ovulation disorders (usually manifested as oligo- or amenorrhea). In addition, 30-40% of women with PCOS have impaired glucose tolerance, and a defect in the insulin signalling pathway seems to be implicated in the pathogenesis of insulin resistance. For this reason, insulin-lowering medications represent novel approach in women with PCOS. The aim of this study was to evaluate the effects of myo-inositol (MYO), an isoform of inositol, belonging to the vitamin B complex, in the treatment of cutaneous disorders like hirsutism and acne. METHODS: Fifty patients with PCOS were enrolled in the study. BMI, LH, FSH, insulin, HOMA index, androstenedione, testosterone, free testosterone, hirsutism and acne were evaluated at the baseline and after receiving MYO therapy for 6 months. RESULTS: After 3 months of MYO administration, plasma LH, testosterone, free testosterone, insulin and HOMA index resulted significantly reduced; no significant changes were observed in plasma FSH and androstenedione levels. Both hirsutism and acne decreased after 6 months of therapy. DISCUSSION: MYO administration is a simple and safe treatment that ameliorates the metabolic profile of patients with PCOS, reducing hirsutism and acne.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“Recently, it has become clear that a frequent feature of women with PCOS is impaired glucose tolerance and insulin resistance accompanied by compensatory hyperinsulinemia, and increasing evidence suggests that hyperinsulinemia plays an important role in the pathogenesis of PCOS [10,11].”
BackgroundNESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“DCI administration has been demonstrated to reduce insulin resistance both in lean and obese patients with PCOS improving ovarian function and decreasing hyperandrogenism [23,24].”
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313 · cited 1×
“Metformin, a biguanide, is the most commonly used insulin sensitiser for the approach of PCOS [39] but is associated with a higher incidence of side-effects such as nausea, vomiting and other gastrointestinal disturbances [40].”
BackgroundGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188
Cited by
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106
“Several follow-up studies supported these findings and the idea that MI exerts beneficial effects on ovulation and oocyte quality [18–21].”
ResultKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“MI 1200–4000 mg daily [77,78,81] • Improved insulin sensitivity • Reduced BMI • Decreased testosterone levels • Decreased plasma LH levels and LH/FSH ratio • Decreased FG score • Improved menstrual cycle • Improved ovulation rate”
BackgroundMethodInositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69
“circulating androgens, elevating the levels of SHBG, reducing the LH to FSH ratio and ameliorating the clinical features of hyperandrogenemia such as hirsutism and acne [37,46,48,49].”
BackgroundShokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63
Angik, R. (2015) · International Journal of Reproduction, Contraception, Obstetrics and Gynecology · doi:10.5455/2320-1770.ijrcog20150234 · Cited by 33
Metadata
- Authors
- Zacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M., & Ferrari, A.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 25
- Issue
- 8
- Pages
- 508-513
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2040559403
- Cited by
- 91
- References
- 11
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. https://app.cochat.ai/papers/10.1080/09513590903015544
- The paper
- Zacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M., & Ferrari, A. (2009). Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecological Endocrinology. https://doi.org/10.1080/09513590903015544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.